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Abstract: Helicobacter pylori is associated with the onset of gastritis, peptic ulcers, and gastric cancer. 
Galectins are a family of β-galactoside-binding proteins involved in diverse biological phenomena. 
Galectin-2 (Gal-2), a member of the galectin family, is predominantly expressed in the 
gastrointestinal tract. Although some galectin family proteins are involved in immunoreaction, the 
role of Gal-2 against H. pylori infection remains unclear. In this study, the effects of Gal-2 on H. pylori 
morphology and survival were examined. Gal-2 induced H. pylori aggregation depending on β-
galactoside and demonstrated a bactericidal effect. Immunohistochemical staining of the gastric 
tissue indicated that Gal-2 existed in the gastric mucus, as well as mucosa. These results suggested 
that Gal-2 plays a role in innate immunity against H. pylori infection in gastric mucus. 
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1. Introduction 
Helicobacter pylori is a helix-shaped Gram-negative bacterium with high motility. It was first 
identified in the stomach of chronic gastritis patients by Marshall and Warren in 1983 [1]. Until the 
discovery of the bacterium, the stomach had been regarded as a sterile organ due to its acidic internal 
environment. H. pylori expresses urease, which hydrolyzes urea to ammonia and carbon dioxide, and 
this enzyme allows the bacterium to survive in the acidic environment of the stomach. 
H. pylori can cause several diseases including gastritis, peptic ulcer, mucosa-associated lymphoid 
tissue lymphoma, and gastric cancer [2,3]. As the bacterium was categorized as ‘Group 1′ (which is 
carcinogenic to humans) by the International Agency for Research on Cancer [4], the major drug 
therapy for gastritis and peptic ulcer has turned to antibiotics against H. pylori from the use of 
antacids. A combined drug therapy consisting of clarithromycin, amoxicillin, and proton pump 
inhibitors is covered by Japan’s National Health Insurance to eradicate the bacterium in positive 
patients. Although the widespread use of this therapy reduced the morbidity of H. pylori-mediated 
peptic ulcers and gastric cancer [5,6], the bacterium eradication efficacy remained approximately 70% 
due to the appearance of clarithromycin resistant bacterium [7]. The bactericidal efficacy of secondary 
therapy substituting metronidazole for clarithromycin is approximately 80% [8] and the value is 
suspected to decrease in the future due to the speculated appearance of the antibiotic-resistant 
bacterium [9]. In addition, amoxicillin cannot be prescribed to patients with penicillin allergy. 
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Therefore, the development of novel therapeutic strategies with a higher bactericidal efficacy and 
applicability to a wide range of H. pylori-positive patients is desired. 
Galectins are a family of animal lectins with affinity to β-galactosides of glycoconjugates and are 
involved in a wide variety of biological phenomena such as cell adhesion, migration of leukocytes, 
differentiation, and apoptosis. Fifteen members of the galectin family proteins have been found in 
mammalian species [10]. Galectins are classified into three types based on their molecular 
architectures, i.e., proto-type, chimera-type, and tandem repeat-type; proto- and chimera-types have 
one carbohydrate recognition domain (CRD) for β-galactosides in a molecule and the tandem repeat-
type has two CRDs [11]. Proto-type galectins can form noncovalent symmetric dimers depending on 
their concentrations and the surrounding environment. The other galectins are also capable of 
forming dimers or oligomers. Thus, galectins can crosslink glycoconjugates possessing β-galactoside 
structures. 
H. pylori, similar to other typical Gram-negative bacteria, possess an outer membrane consisting 
of phospholipids and lipopolysaccharide (LPS), with fucosylated O-antigen of LPS [12]. The 
fucosylated O-antigen of H. pylori mimics Lewis antigens found on the epithelial cells and mucins in 
the human stomach, allowing H. pylori to avoid the host immunity [13,14]. These LPS can be 
crosslinked by galectins. Notably, some galectin family proteins such as galectin-3 (Gal-3), -4, and -9 
are expressed in the gastrointestinal tract, recognize pathogens, and kill them [15]. Gal-3 is involved 
in innate immunity by inducing the aggregation of H. pylori and then killing the bacteria in an O-
antigen-dependent manner [16,17]. 
Gal-2 is localized in gastrointestinal epithelium cells and is specifically expressed in surface 
mucous cells and mucous neck cells in the stomach [18–20]. Previously, our in vitro study suggested 
that Gal-2 could strengthen the barrier structure of the gastric mucosa by crosslinking mucins [21]. 
Acute and chronic colitis in mice was ameliorated by Gal-2 overexpression [22]. In human gastric 
cancer tissues, Gal-2 expression is decreased by lymph node metastasis of gastric carcinoma [23], with 
reduced Gal-2 expression observed at mice lesion sites bearing Helicobacter-induced gastric cancer 
[24]. Like Gal-3, Gal-2 may play several crucial roles for biophylaxis against H. pylori infection. 
In this study, we assessed whether Gal-2 was involved in host immunity against H. pylori. The 
effect of Gal-2 on the aggregation and growth of H. pylori were observed and the β-galactoside-
dependency was investigated. The bactericidal effect of Gal-2 on H. pylori was evaluated by using 
fluorescence dyes to specifically stain live or dead bacterial cells. Moreover, the distribution of Gal-2 in 
the gastric mucus was examined to identify the potential interacting site of Gal-2 with H. pylori in vivo. 
2. Results 
2.1. Gal-2 Induces Aggregation of H. pylori 
To verify whether Gal-2 affected the formation of H. pylori aggregates, the bacterial suspension 
was mixed with Gal-2 for 1 h and then observed under an optical microscope (Figure 1). Several 
clumps of H. pylori, of different sizes and shapes, were formed following the addition of rat Gal-2 
(rGal-2) as shown in Figure 1A; no bacterial aggregation was observed following the addition of 
phosphate-buffered saline (Figure 1B). The relationship between the H. pylori aggregation and Gal-2 
concentration was investigated by counting the nonaggregated bacteria owing to the nonuniformity 
of clumps (Figure 1B). The number of nonaggregated bacteria was reduced with increasing Gal-2 
concentrations. The effect of human Gal-2 (hGal-2) was approximately comparable to rGal-2, that is, 
no great species difference was observed between rats and humans in the H. pylori aggregation effects 
induced by Gal-2. 
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Figure 1. Aggregation of Helicobacter pylori-induced by Gal-2. (A) H. pylori suspension was observed 
under an optical microscope 1-h after mixing with the rat Gal-2 (rGal-2) solution. (B) The bacterial 
suspension after mixing with phosphate-buffered saline. (C) Relationship between bacterial 
aggregation and concentration of Gal-2. The black, dark gray, and light gray bars represent the control 
(without Gal-2), rGal-2, and hGal-2, respectively. Scale bar represents 10 µm. Each bar represents the 
mean ± standard deviation (SD) from five image samples. **, p < 0.01 by Dunnet’s test (vs. control). 
2.2. Gal-2-H. pylori Interaction Depends on β-galactosides 
To evaluate whether the aggregation of H. pylori by Gal-2 was induced via the recognition of β-
galactoside-containing glycoconjugates on the bacteria, the effect of competitive sugars on the Gal-2 
dependent aggregation of H. pylori was investigated (Figure 2). The addition of 0.1 M lactose, which 
contains a β-galactoside structure, to the H. pylori suspension inhibited rGal-2 and hGal-2 dependent 
bacterial aggregation; sucrose, which has no β-galactoside structure, failed to inhibit aggregation. No 
marked species differences were observed between rats and humans in the β-galactoside dependency. 
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Figure 2. Inhibition of Gal-2 induced H. pylori aggregation by competitive sugar, lactose. (A) Number 
of nonaggregated bacteria under the lactose coexistence condition. (B) Number of nonaggregated 
bacteria under sucrose coexistence condition. Concentration of Gal-2 added was 93.9 µg/mL; 
concentrations of lactose and sucrose were 0.1 M. Black, dark gray, and light gray bars represent the 
control (without Gal-2), rGal-2, and hGal-2, respectively. Each bar represents mean ± SD from five 
image samples. **, p < 0.01 by Dunnet’s test (vs. control). 
To confirm that Gal-2 exists in the H. pylori clumps, a green fluorescent protein (GFP)-tagged 
rGal-2 was added, instead of Gal-2, to the H. pylori suspension, which was then observed under 
optical and fluorescence microscopes (Figure 3). In the H. pylori suspension (control), no clumps and 
fluorescence were observed (Figure 3A). When rGal-2-GFP was added to the suspension, bacterial 
aggregation was noted and the fluorescence from rGal-2-GFP was located on the clumps (Figure 3B). 
The phenomena induced by the addition of rGal-2-GFP disappeared under lactose coexistence 
conditions (Figure 3C), whereas sucrose failed to influence this phenomenon (Figure 3D). These 
results suggest that Gal-2 induced the aggregation of H. pylori through the crosslinking of β-
galactoside-containing glycoconjugates on the bacteria. 
 
Figure 3. Observation of rGal-2-GFP-H. pylori interaction. (A) Control (without Gal-2 and sugars). (B) 
rGal-2-GFP alone. (C) rGal-2-GFP with lactose. (D) rGal-2-GFP with sucrose. Upper (1) and lower (2) 
images are transmission and fluorescence images, respectively. The concentration of rGal-2-GFP 
added was 93.9 µg/mL; concentrations of lactose and sucrose were 0.1 M. Scale bars represent 10 µm. 
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 12 
 
2.3. Gal-2 Inhibits H. pylori Growth 
The influence of Gal-2 on the growth of H. pylori was evaluated by increased turbidity of 
bacterial suspension (measured as optical density ratio at 600 nm), before and after incubation with 
the protein for 3 days (Figure 4). Higher the Gal-2 concentration, the stronger the inhibitory effect on 
bacterial growth. Both rGal-2 and hGal-2 significantly inhibited bacterial growth at concentrations 
exceeding 93.9 µg/mL. 
 
Figure 4. Inhibitory effect of Gal-2 on H. pylori growth. The growth rate of H. pylori is represented as 
the optical density ratio at 600 nm (OD600) before and after incubation for 3 days. The black, dark gray, 
and light gray bars represent control (without Gal-2), rGal-2, and hGal-2, respectively. Mean ± SD of 
the results obtained from four samples. *, p < 0.05; **, p < 0.01 by Dunnet’s test (vs. control). 
2.4. Gal-2 has Bactericidal Effects against H. pylori 
To evaluate the bactericidal effect of Gal-2, the H. pylori suspension was incubated with Gal-2 
for 1 h and then stained with carboxyfluorescein diacetate (CFDA) and propidium iodide (PI), for 
live and dead cells, respectively (Figure 5). In the control, only green fluorescence of CFDA was 
observed under the fluorescence microscope and thus most bacteria observed under optical 
microscopes were alive (Figure 5A). When H. pylori was incubated with Gal-2, the red fluorescence 
of PI was observed (Figure 5B,C). The central region of the clumps was stained with PI, although the 
cells surrounding the clumps were barely stained with CFDA. Conversely, most nonaggregated 
bacteria were stained with CFDA. These results suggested that rGal-2 and hGal-2 showed bactericidal 
effects against H. pylori. 
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 12 
 
 
Figure 5. Bactericidal effect of Gal-2 against H. pylori. (A) Control (without Gal-2). (B) rGal-2. (C) hGal-
2. Upper (1) and lower (2) images are transmission and fluorescence images, respectively. Live and 
dead H. pylori cells were stained with carboxyfluorescein diacetate (CFDA; green) and propidium 
iodide (PI; red), respectively, for 10 min. The concentration of Gal-2 was 93.9 µg/mL. Scale bars 
represent 10 µm. 
2.5. Gal-2 Distributes in Gastric Mucus 
Distribution of Gal-2 in the gastric mucosa and mucus of mice was evaluated by periodic acid-
Schiff (PAS) staining and immunohistochemistry (IHC) with the anti-galectin-2 antibody. The 
mucosa and mucus of mice were simultaneously fixed using Carnoy’s solution. PAS staining 
visualized the mucus that existed just above the mucosa (Figure 6A). Gal-2 was observed in the 
mucus and mucosa by IHC (Figure 6C), which could not be considered a nonspecific reaction (Figure 
6B). It is possible that Gal-2 induces the aggregation of H. pylori and then demonstrates the 
bactericidal effect in gastric mucus. 
 
Figure 6. Distribution of Gal-2 in gastric mucus. (A) Periodic acid-Schiff (PAS) staining. (B) Isotype 
control. (C) Anti-mouse Gal-2 antibody. Upper and lower parts of these images are the luminal side 
and basolateral surface, respectively. The black dotted lines indicate gastric mucosal surface. Scale 
bars represent 50 µm.  
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3. Discussion 
The immune response against pathogens is one of the important biological functions mediated 
by galectins. The pathogen recognition and killing abilities of galectin-1, -3, and -8 have been 
extensively investigated; however, data on Gal-2 is lacking [15]. In this study, we observed that Gal-
2 could be involved in host immunity against H. pylori infection. The aggregation of H. pylori was 
induced by Gal-2 through crosslinking of the β-galactoside structures on the bacteria, producing a 
bactericidal effect. 
The aggregation of H. pylori depended on the concentration of Gal-2 (Figure 1). Gal-2 can 
crosslink β-galactoside structures by forming homodimers [25]. The crosslinking via β-galactoside-
containing glycoconjugates on H. pylori can induce bacterial aggregation. The aggregation induced 
by Gal-2 was inhibited by lactose, which possesses a β-galactoside structure (Figure 2). When rGal-
2-GFP was added to the H. pylori suspension, fluorescence was detected on the clumps (Figure 3). 
Gal-2 may induce H. pylori aggregation by crosslinking LPS on the bacterial cell surface. H. pylori 
(ATCC43504) has Lewis X, Lewis Y, and H type I within the LPS as O-antigens [12]. Reportedly, Gal-
3 binds to the O-antigen of H. pylori [16], with Gal-2 demonstrating an affinity to H type I in vitro [26]. 
It is possible that Gal-2 crosslinks H type I expressed on H. pylori cells, producing clumps. Further 
investigations are imperative to elucidate the detailed mechanism. 
Additionally, several free H. pylori cells, which were not involved in the aggregation induced by 
Gal-2, were observed (Figure 1). Following the addition of rGal-2-GFP, no fluorescence was detected 
on the free H. pylori (Figure 2). These H. pylori may possess minimal or no β-galactoside-containing 
glycoconjugates. Furthermore, even if rGal-2-GFP bound to these H. pylori, the fluorescence may be 
extremely weak to be detected by the fluorescence microscope owing to the low density of the protein. 
H. pylori has various types of carbohydrate chains containing the O-antigen. The O-antigen 
expression of H. pylori is altered by the environment surrounding the bacteria, e.g., pH and host 
immunity [27,28]. The expression fluctuates based on the LPS phase variation, even in an identical 
colony [29]. Thus, free bacteria may have little or no β-galactoside-containing glycoconjugates. 
The aggregation of H. pylori by Gal-2 could occur as follows: Gal-2 binds to β-galactoside-
containing glycoconjugates of a bacterium via one CRD of the dimer; the Gal-2-binding bacterium 
binds to another bacterium with or without Gal-2 via the another CRD of the dimer. No great species 
differences were observed in the aggregation effects induced by Gal-2 between rats and humans 
(Figure 1), consistent with the similarities observed in their Gal-2 amino acid sequence [30]. 
Gal-2 inhibited H. pylori growth and demonstrated a bactericidal effect (Figure 4; Figure 5). H. 
pylori in the center of clumps induced by Gal-2 were dead, with the bacterium in the surrounding 
barely survived. Gal-3 induces ATP metabolic disorders and morphological alterations in the H. pylori 
cell wall [17]. Gal-4 and Gal-8 kill blood group B positive Escherichia coli by disrupting the bacterial 
membrane morphology [31]. It can be postulated that Gal-2 disrupts the metabolic functions and 
membrane integrity of H. pylori. Assuming that Gal-2 has a bactericidal effect by binding to the β -
galactoside structure of H. pylori, the more the protein binds to the bacteria, the greater the bacterial 
damage. Thus, the dead bacteria were observed in the center of clumps where the Gal-2 concentration 
was high. Another explanation for the bactericidal effect of Gal-2 is based on the aggregation of H. 
pylori itself. The survival of H. pylori requires the brain heart infusion broth, a highly nutritious 
general-purpose growth medium, and a microaerophilic environment. Hence, the center of the 
clumps might possess inadequate conditions for survival. To understand a detail molecular 
mechanism for the bactericidal effect of Gal-2, further studies including metabolome analysis are 
required. 
The immunoreactivity of Gal-2 overlapped the PAS-positive region around the mouse mucosa; 
hence, Gal-2 existed in the mouse gastric mucus, as well as mucosa (Figure 6). The growth of H. pylori 
was inhibited by Gal-2 at concentrations above 93.9 µg/mL (Figure 4). Although the concentration of 
Gal-2 in the gastric mucosal epithelium is unknown, the protein exists at about 15 ng/mL in the serum 
[32]. In the spleen, the galectin-1 expression is 35–40 µg/mL, which is much higher than in the serum 
[32,33]. Furthermore, it is speculated that the Gal-2 expression in gastrointestinal cells is substantially 
higher than in the serum. Expression levels of galectins alter dramatically under various conditions, 
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including pathogenic infections or disease progression [34]. Gal-3 expression in the stroma of the 
stomach is elevated following an H. pylori infection [35]. Therefore, we anticipated that the Gal-2 
concentrations used in this study were within physiological limits. Because the aggregation effect of 
Gal-2 was confirmed within pH 5 to 7 (data not shown), the clumps of H. pylori can be formed in the 
mucus close to mucosa. There are a lot of glycoconjugate-containing substrates in the mucus and the 
substrate may affect the interaction of Gal-2 and H. pylori. Gal-3 was reported to produce H. pylori 
clumps on the mucosal surface [17]. Induction of aggregation, growth suppression and bactericidal 
effects of Gal-2 against H. pylori could occur in the gastric mucus in vivo. Further study is required to 
confirm these effects in vivo. 
In conclusion, Gal-2 demonstrated the induction of aggregation, growth inhibition, and 
bactericidal effects in H. pylori and this protein exists in the gastric mucus. These results suggest that 
Gal-2 is involved in the immune response for the H. pylori infection. These findings could aid in the 
development of novel antibiotics and therapeutic strategies against H. pylori infection. Although the 
structural modification of Gal-2 using protein engineering or formulation design for suitable drug 
delivery might be necessary to prevent side effects such as ischemia risk for coronary artery disease 
patients [36,37], Gal-2 can be used as a substitute to conventional antibiotics. 
4. Materials and Methods 
4.1. H. pylori and Growth Condition 
The H. pylori strain, ATCC43504, was purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and the bacteria were stored at –80 °C as a glycerol stock solution. The 
dissolved stock was inoculated into a selective agar medium (Nissui Pharmaceutical, Tokyo, Japan) 
and incubated in a jar conditioned with Anaeropack microaerophilic (Mitsubishi Gas Chemical, 
Tokyo, Japan) at 37 °C for 4 days. The colonies that appeared were employed for subsequent 
experiments and subculture. 
4.2. Preparation of H. pylori Suspension 
H. pylori colonies were harvested and suspended in Hank’s balanced salt solution (HBSS, 
Invitrogen, Carlsbad, CA, USA). Nonsuspended bacteria were removed by centrifugation. The 
supernatant was adjusted to 1.0 of optical density at 600 nm (OD600). The suspension was used in the 
following experiments. Approximately, 108 colony-forming unit (CFU)/mL corresponded to 0.5 of 
OD600. 
4.3. . Purification of Recombinant Galectin Proteins 
The expression and purification of the recombinant rat Gal-2 (rGal-2), green fluorescent protein-
tagged rat Gal-2 (rGal-2-GFP), and human Gal-2 (hGal-2) were performed using pET21a vector 
(Novagen, Merk KGaA, Darmstadt, Germany) as previously described [38,39]. Briefly, E. coli cells 
were incubated and subjected to protein expression by adding isopropyl-β-thiogalactopyranoside. 
These cells were harvested and sonicated; the debris was removed by centrifugation. The 
recombinant protein was purified by adding the extract to the β-galactoside-immobilized column. To 
remove LPS, Detoxi-Gel (Thermo Fisher Scientific, Fremont, CA, USA) was added to the purified 
protein solution and the mixture was incubated at 4 °C for 30 min with mixing. The resin was 
removed by centrifugation. The supernatant was filtered at 0.2 µm and used for experiments. 
4.4. Aggregation Assay 
The aggregation assay was performed as previously described with a slight modification [40]. 
Briefly, 100 µL of the H. pylori suspension was added to the equivalent Gal-2 solution and incubated 
for 1 h at 37 °C. After the mixture was vortexed for 2500 rpm, the sample (2 µL) obtained from the 
mixture was loaded on a microscope slide and covered with a coverslip (1.8 mm × 1.8 mm). The 
sample was observed using a microscope (BX-51, Olympus, Tokyo, Japan, 40x/numerical aperture; 
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0.95) equipped with a digital camera (DP-26, Olympus), and five images were randomly taken. The 
concentration of nonaggregated bacteria was calculated as follows: the number of bacteria/µL = the 
number of bacteria per constant area (0.2 mm × 0.2 mm) × 40.5. Nonaggregated bacteria were 
determined as described above [41]. In brief, bacteria existing alone or two linearly connected bacteria 
were classified as nonaggregated. Aggregation effects of Gal-2 were also investigated under 0.1 M 
lactose or sucrose conditions. 
4.5. Inhibitory Activity of Gal-2 against H. pylori Growth 
Briefly, 100 µL of the brain heart infusion broth (Becton Dickinson, Cockeysville, MD, USA) 
containing 0.1% glucose and 10% fetal bovine serum (GE Healthcare, Piscataway, NJ, USA) and 50 
µL of Gal-2 solution were added to a 96-well plate. Next, 50 µL of the bacterial suspension diluted to 
0.1 of OD600 was applied to the plate and was cultured under microaerophilic conditions at 37 °C for 
2 days. OD600 of the cultures were measured after resuspension by vortexing at 1000 rpm for 5 min. 
The growth rate of the bacteria was determined by comparing the bacterial OD600 before and after 
incubation. 
4.6. Bactericidal Effect of Gal-2 
Briefly, 100 µL of the bacteria suspension was added to an equivalent Gal-2 solution and 
incubated at 37 °C for 1 h. CFDA (Dojindo, Kumamoto, Japan) and PI (Dojindo) were added to the 
mixture at final concentrations of 0.15 mg/mL and 1 µg/mL, respectively, according to the 
manufacturer’s instructions. The mixture was observed under a microscope (BX51, Olympus, Filter; 
NIBA and WIG) equipped with a charge-coupled-device camera (Hamamatsu, Shizuoka, Japan). 
4.7. Preparation of Mouse Gastric Tissue Section 
C57BL/6J male mice were purchased from Clea Japan (Tokyo, Japan). The animal experiments 
were reviewed and approved by the Institutional Animal Care and Use Committee of the Josai 
University and performed in accordance with the institutional guidelines (JU19091). 
The mice were killed by cervical dislocation and the stomach were isolated. After the gastric 
contents were removed, the stomach was incised along the greater curvature. The specimen was fixed 
using cold Carnoy’s solution (Ethanol: Chloroform: Acetic acid = 6: 3: 1) for 2 h according to Ota et al. 
[42]. The fixed tissue was incubated with 10, 15, and 20% sucrose for 2 h, sequentially. The tissue was 
embedded in O.C.T. compound (Sakura FineTechnical, Tokyo, Japan) and frozen with dry 
ice/acetone. Tissue sections of 10 µm thickness were obtained using the Cryostat (CM3050S, Leica, 
Germany) and mounted on MAS coated microscope slides (Matsunami Glass, Osaka, Japan). 
4.8. PAS Staining and IHC 
Gastric tissue specimens were refixed before staining. PAS staining was performed using a 
staining kit (Mutoh Chemistry, Tokyo, Japan) according to the standard protocol. 
For IHC, tissue sections were immersed in 0.3% hydrogen peroxide in methanol at room 
temperature for 30 min to inactivate endogenous peroxidase. The nonspecific reaction was blocked 
by incubation with normal goat serum (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) at 
room temperature for 20 min. The sections were incubated with rabbit antibodies against mouse Gal-
2 (1:700; Cloud-Clone Corp. Houston, TX, USA) as a primary antibody at 4 °C overnight and followed 
with the secondary antibody (Vectastain ABC kit) at room temperature for 1 h. Rabbit IgG against 
keyhole-limpet hemocyanin (Abcam, Cambridge, USA) was used as an isotype control to exclude 
nonspecific reactions. To enhance the color reaction, the VECTASTAIN ABC reagent (Vectastain ABC 
kit) was applied to the sections and incubated at room temperature for 30 min. The specific reactions 
were visualized using 0.02% 3,3′-diaminobenzidine in 0.05 M Tris-HCl (pH 7.4), containing 0.005% 
hydrogen peroxide and counterstained with hematoxylin. The visualized reactions were observed 
using a microscope (BZ-X800, Keyence, Osaka, Japan, 40x/numerical aperture; 0.95). 
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